Therapeutic integration of signal transduction targeting agents and conventional anti-cancer treatments.

in Endocrine-Related Cancer
Authors:
D Melisi Cattedra di Oncologia Medica, Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Università degli Studi di Napoli "Federico II", Naples, Italy.

Search for other papers by D Melisi in
Current site
Google Scholar
PubMed Close
,
T Troiani Cattedra di Oncologia Medica, Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Università degli Studi di Napoli "Federico II", Naples, Italy.

Search for other papers by T Troiani in
Current site
Google Scholar
PubMed Close
,
V Damiano Cattedra di Oncologia Medica, Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Università degli Studi di Napoli "Federico II", Naples, Italy.

Search for other papers by V Damiano in
Current site
Google Scholar
PubMed Close
,
G Tortora Cattedra di Oncologia Medica, Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Università degli Studi di Napoli "Federico II", Naples, Italy.

Search for other papers by G Tortora in
Current site
Google Scholar
PubMed Close
, and
F Ciardiello Cattedra di Oncologia Medica, Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Università degli Studi di Napoli "Federico II", Naples, Italy.

Search for other papers by F Ciardiello in
Current site
Google Scholar
PubMed Close
DOI:
https://doi.org/10.1677/erc.0.0110051
Volume/Issue:
Volume 11: Issue 1
Article Type:
Abstract
Page Range:
51–68
Online Publication Date:
Mar 2004
Free access

Sign up for journal news

The currently available treatment of cancer patients is based on the use of cytotoxic drugs and/or of ionizing radiations, which have potent antitumor activity, but also cause clinically relevant side effects, since they affect cellular targets that are common to both cancer cells and normal proliferating cells. In the past 20 years, the discoveries on the molecular mechanisms of cancer development and progression have prompted the search for agents which are more selective for cancer cell molecular targets. The possibility of combining conventional cytotoxic drugs with novel agents that specifically interfere with key pathways controlling cancer cell survival, proliferation, invasion and/or metastatic spreading has generated a wide interest. This could be a promising therapeutic approach for several reasons. First, since the cellular targets for these agents and their mechanism(s) of action are different from those of cytotoxic drugs, it is possible for their combination with chemotherapy without cross-resistance. Second, alterations in the expression and/or the activity of genes that regulate mitogenic signals not only can directly cause perturbation of cell growth, but also may affect the sensitivity of cancer cells to conventional chemotherapy and radiotherapy. In this review, we will discuss the biologic bases of the combination of molecular targeted drugs with conventional medical cancer treatments and the available results of the first series of clinical trials in cancer patients.

Endocrine-Related Cancer is committed to supporting researchers in demonstrating the impact of their articles published in the journal.

The two types of article metrics we measure are (i) more traditional full-text views and pdf downloads, and (ii) Altmetric data, which shows the wider impact of articles in a range of non-traditional sources, such as social media.

More information is on the Reasons to publish page.

Sept 2018 onwards Past Year Past 30 Days
Full Text Views 327 224 30
PDF Downloads 111 53 2

 

  • Collapse
  • Expand
Print ISSN:
1351-0088
Online ISSN:
1479-6821
Page(s):
18
Print Publication Date:
01 Jan 2004
Online Publication Date:
Mar 2004